







Automatic Breast Density Measurement and Prognostic Methods of Postoperative Tamoxifen Therapy for Breast Cancer

Hui Li¹, Jiao Li², Haojiang Li², Shuchao Chen¹, Lizhi Liu² and Hongbo Chen¹

¹Life and Environmental Sciences College, Guilin University of Electronic Technology, Guilin, China

²Sun Yat-sen University Cancer Center, Guangzhou, China

Keywords: Breast Cancer, Mammographic Density, Deep Learning, Breast Cancer Prognosis.

Abstract: In order to explore a prognostic analysis method of postoperative tamoxifen treatment for breast cancer from mammography, the squeeze-and-convolutional Neural Network (SE-CNN) method was used to investigate the model of mammographic density automatic extraction from mammography and the prognostic effect of mammographic density on tamoxifen treatment for breast cancer. The results show that the mammographic density change rate of the subjects before and 15 months after surgery was extracted, and the mammographic density change rate cut value was obtained by density map method, and the subjects were divided into groups. The progression-free survival was HR: 2.654(95%CI,1.102-6.395), P =0.030. Patients with high mammographic density change rate had a better prognosis, while those with low mammographic density change rate had a worse prognosis. It is concluded that mammographic density change rate value can be a potential prognostic factor of postoperative tamoxifen treatment for breast cancer.


1 INTRODUCTION


Breast cancer is the most common cancer in women and the leading cause of cancer deaths in women worldwide (Siegel 2020, Peng 2020, Deng 2020). Endocrine therapy is an important part of the comprehensive treatment of breast cancer (Oladeru 2020) and plays an important role in the prevention of postoperative recurrence and metastasis of breast cancer (Chlebowski 2021). Tamoxifen is an estrogen receptor antagonist, which can combine with estrogen receptors on the cell membrane to form a complex, thus preventing estrogen from playing a role, and is an important postoperative treatment for breast cancer (Rahem 2020). It is of great clinical significance to study the key prognostic factors of postoperative tamoxifen treatment for breast cancer.


In recent years, some researchers have been committed to studying the prognostic factors of postoperative tamoxifen treatment for breast cancer from the perspective of bioinformatics. Flap endonuclease-1(Xu 2021), PDHA2-APRT gene pair


(Lv 2019), MFG-AS1(Feng 2020), etc., have been considered as important prognostic biomarkers for breast cancer after tamoxifen treatment. CXCL10 can be used as a biomarker to predict the prognosis of breast cancer and as a therapeutic target for tamoxifen resistance (Wu 2020). The high expression of TRAF4 predicts a poor prognosis in the treatment of breast cancer with tamoxifen, and promotes tamoxifen resistance (Zhou 2020). In addition, there are some studies looking for prognostic markers from medical images. For example, surface dispersion coefficient in magnetic resonance imaging has been proved to be a marker that can be used to evaluate the effectiveness of tamoxifen in the treatment of breast cancer (Zhai 2013).


Mammography is the most common examination method for breast cancer patients, and it is of clinical significance to obtain accurate prognostic markers from mammography. Mammographic density (MD) refers to the proportion of breast glandular tissue in the overall projection of the breast in Mammographic images (Sherratt 2016). It is a measure of the relative quantity of glandular tissue in the breast (Bell 2020)


 <https://orcid.org/0000-0002-6110-6920>

 <https://orcid.org/0000-0002-8980-2899>

 <https://orcid.org/0000-0003-0784-1235>

 <https://orcid.org/0000-0002-3579-4812>

 <https://orcid.org/0000-0001-7875-9074>

 <https://orcid.org/0000-0002-7063-5410>

and has been proved to be related to the sensitivity and specificity of breast cancer screening (Lynge 2019). MD has been proposed as a biomarker to predict the risk of breast cancer, the possibility of cancer recurrence, the response to neoadjuvant chemotherapy and survival rate (King 2011). Changes in MD reflect changes in the amount of collagen and epithelial and non-epithelial cells in mammary gland (Boyd 2011). MD is not a static characteristic, and unlike most breast cancer risk factors, MD can be changed (Boyd 2011), and the change of MD is associated with the increased risk of breast cancer, advanced tumor stage at diagnosis, local recurrence and the increased risk of the second primary cancer (Huo 2014). Increased MD is associated with increased risk of breast cancer, and reduced MD is accompanied by reduced risk (Román 2019).

In clinical practice, MD is obtained primarily on the basis of subjective visual assessments that rely on radiologists, and has been shown to have significant intra-physician and inter-physician variability. Cumulus Software, a quantitative imaging analysis software, has been developed for quantitative measurement of dense tissue in breast by molybdenum target (Byng 1998), which is the gold standard for MD measurement (Nguycn 2018, Boyd 2010, Kerlikowske 2015). This is a semi-automatic observer aid based on an interactive threshold. The observer subjectively selects a threshold gray level that facilitates recognition, separating glandular tissue from fat. The interactive computer-aided segmentation program based on the K-means clustering algorithm measured MD, requiring manual judgment of whether it was pectoral muscle, and then segmental glandular tissue based on the K-means clustering algorithm, and then calculated MD (Glide 2007). However, these semi-automatic MD measurement methods require training of observers and the measurement results are subject to subjective factors of observers. A gland probability map is generated in the method of MD estimation based on Deep Convolutional Neural Network (DCNN), and MD is estimated according to the ratio of the gland probability map to the breast area (Li 2018). Segmentation of breast and dense fibroglandular region based on full convolutional network, this method uses VGG16 network as the basic network structure and fine-tuning network to achieve segmentation of breast and gland dense region respectively (Lee 2018). However, the MD distribution of each patient was different, and the mammary gland in some molybdenum target images showed scattered distribution, dark gray scale and fine structure. Deep learning probability maps or

segmentation methods can better segment the dense areas of glands, but some non-densely aggregated glandular tissues are often ignored, resulting in deviations between measured MD and the actual value.

Aiming at the existing problems in breast density measurement, we proposed an automatic breast density measurement method based on deep learning. Firstly, the deep learning method is used to achieve the precise segmentation of breast region. Then, the Squeeze-and-Excitation Convolutional Neural Network (SE-CNN) for MD is used to realize the automatic measurement. To obtain accurate MD value of breast cancer patients. In order to study the key factors for the evaluation of postoperative tamoxifen treatment for breast cancer, we analyzed the prognostic capability of Mammographic density change ratio (MDCR) before and after treatment to explore the prognostic analysis method of postoperative tamoxifen treatment for breast cancer. This paper attempts to find breast cancer patients with good postoperative tamoxifen treatment effect from the perspective of imaging and improve the treatment effect of breast cancer.

2 MATERIALS AND METHODS

2.1 Dataset

This study was approved by the Ethics Committee of Cancer Center of Sun Yat-sen University with the approval number szR2020-170. The data were all from the Cancer Prevention and Treatment Center of Sun Yat-sen University, and there were two independent data sets, model data and prognostic data. The model data was used to train the MD automatic measurement model, and the prognostic data was used to obtain MDCR, and to analyze the prognosis of postoperative tamoxifen treatment for breast cancer.

2.1.1 Model Data

In the training of MD automatic measurement model, due to the subjectivity and inaccuracy of manual labeling threshold when setting threshold label in SE-CNN threshold regression network model, Selenia Dimensions instrument newly introduced by Cancer Prevention and Treatment Center of Sun Yat-sen University can indirectly obtain the gray threshold of gland area. This label can avoid the error caused by manual labeling. Therefore, data from the machine were used to train the MD automatic measurement

model, including 246 molybdenum target images from 246 patients, which were collected from March 2021 to June 2021, and the image resolution was 1136×944.

2.1.2 Prognostic Data

In this dataset, there were 858 mammographic images with a resolution of 1915×2295. The data set was from 429 patients. The patients were first treated from April 2008 to December 2015. During follow-up, all patients were treated with tamoxifen according to the NCCN Breast Cancer Clinical Practice Guidelines (8th edition) (Gradishar 2021). The time points of molybdenum imaging were before surgery and 15 months after endocrine therapy for each patient, with a median age of 44(25-61) years, a median height of 158(142-170) cm, and a median weight of 56(35-165) kg. Median follow-up time was 59.8(6-82) months, resulting in overall survival, progression-free survival, distant metastasis-free survival, and regional relapse-free survival.

2.2 Experiment

As shown in Figure 1, this experiment is divided into two parts. The first part is the training and verification of the MD automatic measurement model based on model data, and the model with the best effect is found through the five-fold cross-verification. Then, based on the prognostic data, the MDCR value of the prognostic data was obtained by the MD automatic measurement model, and the prognostic ability of MDCR value as a prognostic factor was obtained by the prognostic analysis method.




Figure 1: Experimental design block diagram.

2.3 MD Automatic Measurement Model

MD refers to the ratio of gland area to breast area, that is, $MD=GA/BA$, where GA and BA represent gland area and breast area respectively. As shown in Figure 2, the U-Net Plus method was firstly used to segment the breast area and obtain the breast area BA. Then the SE-CNN network was used to achieve the gray threshold regression of the breast area and obtain the threshold of gland segmentation in the breast area, so as to realize the extraction of the gland area and obtain the gland area GA. Finally, the MD value was calculated.




Figure 2: Flow chart of MD automatic measurement model.

2.3.1 Breast Region Segmentation based on U-NET Plus Network

U-net Plus network (Chen 2019) performs well in the segmentation of esophageal cancer and esophageal

cancer in 2d CT slices. Its advantage lies in the use of two U-shaped structures to enhance the extraction ability of complex and abstract features, which can effectively solve the problem of irregular and fuzzy boundary segmentation. In the molybdenum target

image used in this paper, the boundary of the breast area is dark and the contour is fuzzy. The U-Net Plus network can effectively complete the segmentation task of the breast area and remove the surrounding muscle and nipple tissues.

After testing, the DICE value of breast region segmentation based on U-NET Plus method reached 0.997, which accurately segmented the breast region. This network can be used for accurate segmentation of breast region in molybdenum target image.

2.3.2 Breast Threshold Extraction based on SE-CNN Network

In molybdenum images, adipose tissue appears to be grayscale smaller, while glandular tissue appears opaque or grayscale larger. Therefore, glandular tissue and adipose tissue can be distinguished according to gray threshold. Since most of the glandular tissues in the breast image are concentrated and a few are scattered, and the glandular tissues have different luminance, the realization of threshold regression requires stronger feature extraction ability of the network. Based on the channel attention mechanism, the SE-CNN model is proposed to meet this requirement. As shown in Figure 3, the model consists of block modules of convolution layer, nonlinear layer and maximum pooling layer. In order to deepen the number of convolution layers, the model uses five block modules to enhance the network's feature extraction capability. At the same time, the model studies the dependencies between the channels. The attention is paid to the channels. The SE(Squeeze-and-Excitation) module is added to each block. Then according to this importance, the useful features are promoted and the useless features are suppressed to improve the accuracy of threshold regression.




Figure 3: Diagram of SE-CNN network structure.

2.4 MDCR Calculation

The objective of this study is to explore the effect of MDCR value on postoperative tamoxifen treatment for breast cancer. The automatic measurement method proposed in this paper calculates the MD values before and after surgery respectively, so as to obtain the change rate of MD, NAMELY, $MDCR=(MD1-MD2)/MD1$, where in MD1 represents the breast density of the patient before surgery, and MD2 represents the breast density of the patient from endocrine therapy to follow-up time.

2.5 Statistical Methods

2.5.1 MD Automatic Measurement Model Evaluation Method

In this paper, deep learning method is used to study the MD automatic measurement model, so as to realize the automatic calculation of MDCR value. The breast area was extracted by U-NET Plus method. In this paper, we propose a method to determine the gland area by determining the threshold value of gland extraction in molybdenum target image, so as to obtain accurate MD value. We used threshold absolute error (MAE), determination coefficient (R^2) and Bland-Altman consistency analysis to evaluate the performance of the new threshold extraction method for glands. They are defined as:

$$MAE = \frac{\sum |value_{predict} - value_{label}|}{num} \quad (1)$$

$$R^2 = 1 - \frac{\sum (value_{predict} - value_{label})^2}{\sum (value_{predict} - value_{label\ mean})^2} \quad (2)$$

2.5.2 Prognostic Evaluation Method

MDCR cutting value was solved by density map method in R language, and patients were divided into groups. K-M survival analysis was used to analyze the effect of single factor on the prognosis of postoperative tamoxifen treatment for breast cancer. When $P < 0.05$, the difference in progression-free survival between the two groups was considered statistically significant. Cox regression analysis, using mathematical model to fit the relationship between survival distribution and impact factors, evaluate the impact of impact factors on the distribution of survival function, further verify the clinical significance of the prognostic method.

3 RESULTS

3.1 MD Automatic Measurement Results and Analysis

In the threshold regression module, the results of AlexNet, Vgg11 and ResNet50 models were compared with se-CNN model. As shown in Table 1, the average absolute error of threshold regression results of SE-CNN network was lower than the other three models, and the determination coefficient was higher than the other three models. It indicates that the threshold regression results of SE-CNN network are more accurate.

Bland-altman consistency analysis was performed for AlexNet, VGG11, ResNet50 and SE-CNN model threshold output and machine threshold

Table 1: Comparison of experimental results of threshold regression model.

	MAE	R ²
AlexNet	12.64±5.88	0.63
VGG11	12.03±6.96	0.67
ResNet50	10.94±5.29	0.70
SE-CNN	10.41±4.78	0.74

label. Figure 4A is bland-Altman diagram of SE-CNN model. It can be seen from the figure4 that 98%(48/49) samples are within the 95% consistency limit. Within the consistency limit, the maximum absolute value of difference between two groups of data is 24.43, and the average value of difference is 0.33. Therefore, compared with the other three models, the threshold result of SE-CNN model has the best consistency and is the most accurate and reliable.




Figure 4: Bland-Altman consistency analysis of threshold regression results.

3.2 MDCR Cut Value and Subjects Were Grouped

In order to analyze the prognosis of postoperative tamoxifen treatment for breast cancer, breast cancer patients need to be grouped. Nuclear density estimates were calculated and plotted using a density map method independent of patient prognostic information. The density map is performed by R's package GGplot2 and the function geom_density (a smoothed version of the histogram). As shown in Figure5A, when the MDCR value is 5.3, the curve reaches its peak and can be used as the optimal cutting value. To evaluate the validity of the cut values, the RMS software package of R was used to perform the

restricted cubic spline (RCS) function, and the Cox regression model of the overall survival rate was established using the RCS formula parameters. As shown in Figure5B, with the increase of MDCR, the risk of breast cancer progression decreases, and the critical value of risk reduction is reached when MDCR=5.3, which further verifies the reliability of cutting value selection. We used MDCR=5.3 as the cut-off value to divide breast cancer patients into two groups and analyze the prognosis of postoperative tamoxifen treatment.




Figure 5: MDCR cutting value analysis.

3.3 Effect Evaluation of Tamoxifen after Breast Cancer Operation

After obtaining MDCR cut values, breast cancer patients were divided into two groups: Group A(MDCR \geq 5.3) and Group B(MDC<5.3). Figure 6 shows the survival curve between the two groups. The P-value of progression-free survival between the two groups was 0.032 by Logrank test. There was a significant difference between the two groups. It can also be found that when MDCR \geq 5.3, the patient survival curve is above, that is, the postoperative tamoxifen treatment effect of this group of breast cancer patients is better than that of the other group. Multivariate Cox regression analysis was shown in Table 2. Similarly, it was found that the risk rate of MDCR was 2.654(95%CI,1.102-6.395), P=0.030. These results suggest that MDCR can be used as a key prognostic factor for postoperative tamoxifen treatment of breast cancer.

Cox regression analysis was used to determine the independent influencing factors of breast cancer progression. Firstly, k-M analysis was performed to screen out some meaningless variables, and factors with p value less than 0.1 were included in Cox regression model. K-M method was used to analyze the following factors: age, height, weight, BMI and MDCR, and the analysis results showed that age, BMI and MDCR were correlated with the progression of breast cancer. The results of Cox multivariate

analysis were shown in Table 2. MDCR (HR=2.654, 95%CI,1.102-6.395, P =0.030), BMI (HR=0.272, 95%CI, 0.088-0.846, P =0.024), Was an independent risk factor for metastasis or recurrence in breast cancer patients treated with tamoxifen. Follow-up breast cancer patients with lower MDCR and higher BMI had an increased risk of metastasis or recurrence.




Figure 6: Survivorship curve.

4 CONCLUSIONS AND DISCUSSIONS

In this paper, the following conclusions were drawn through the study of automatic breast density extraction model and the analysis of postoperative tamoxifen treatment effect for breast cancer.

(1) In order to perform automatic prognostic analysis of breast cancer, this paper proposed a channel attention-based SE-CNN network to accurately calculate breast density from molybdenum target X-ray images. It can be seen from the comparative analysis of performance that the determination coefficient $R^2=0.74$, and from the consistency analysis that 98% of samples are distributed within an acceptable range. Therefore, SE-CNN network can achieve accurate and automatic extraction of MD.

(2) During prognostic analysis, MDCR cutting value was obtained by density method, and the subjects were divided into groups. The progression-free survival between the two groups was HR 2.654(95%CI,1.102-6.395), P =0.030, showing a significant effect. Patients with high MDCR had a better prognosis, while those with low MDCR had a worse prognosis. It indicates that MDCR value can be used as a potential prognostic factor of postoperative tamoxifen treatment for breast cancer, and can assist doctors in finding patients with good prognosis after postoperative tamoxifen treatment for breast cancer.

Table 2: Multivariate Cox multivariate analysis.

	Progression-Free	Recurrence/Metastasis	HR (95%)	P value
Adge/(year)			2.119(95%CI,0.905-4.964)	0.084
<44(n=209)	192	17		
≥44(n=220)	212	8		
BMI			0.272(95%CI,0.088-0.846)	0.024
<22(n=184)	176	8		
≥22(n=245)	228	17		
MDCR			2.654(95%CI,1.102-6.395)	0.030
<5.3(n=220)	202	18		
≥5.3(n=209)	202	7		

The contribution of this paper is mainly in two aspects: 1) It explores a method to automatically obtain accurate MD value, which effectively solves the impact of human intervention on the prognosis of breast cancer. The introduction of channel attention mechanism helps the network model to be more sensitive to glandular tissue and achieve accurate, complete and automatic extraction of glands. 2) The prognostic factors of breast cancer in mammography were explored and verified. MDCR has good prognostic performance in breast cancer and can be used as a prognostic factor for postoperative tamoxifen treatment of breast cancer.

ACKNOWLEDGEMENTS

On the completion of this paper, I would like to express my heartfelt thanks and respect to Hongbo Chen and the students in the research group. This project has been applied for national Natural Science Foundation of China (81760322, 82171906) and university-level innovation Project 2021YCX5174.

REFERENCES

- Bell R. (2020). Mammographic density and breast cancer screening. *Climacteric*, 23, 460-465.
- Boyd N., Martin L. J., Bronskill M., et al (2010). Breast tissue composition and susceptibility to breast cancer. *Journal of the National Cancer Institute*, 102(16), 1224-37.
- Boyd N., Martin L. J., Yaffe M., et al (2011). Mammographic density and breast cancer risk: current understanding and future prospects. *Breast Cancer Research:BCR*, 13, 223-223.
- Byng J., Yaffe M., Jong R., et al (1998). Analysis of mammographic density and breast cancer risk from digitized mammograms. *Radiographics : a review*

- publication of the Radiological Society of North America, Inc, 18(6), 1587-98.
- Chen S., Yang H., Fu J., et al (2019). U-Net Plus: Deep Semantic Segmentation for Esophagus and Esophageal Cancer in Computed Tomography Images. *IEEE Access*, 7, 82867-82877.
- Chlebowski R. T., Aragaki A., Pan K. (2021). Breast Cancer Prevention: Time for Change. *JCO oncology practice*, OP2100343.
- Deng Dajun (2020). World Cancer Report 2020: Adapting cancer prevention strategies to New trends in the cancer epidemic. *Electronic journal of integrated oncology Therapy*, 6(3), 27-32.
- Feng J., Wen T., Li Z., et al (2020). Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. *Aging (Albany NY)*, 12, 20658-20683.
- Glide-Hurst C., Duric N., Littrup P. (2007). A new method for quantitative analysis of mammographic density. *Medical physics*, 34(11), 4491-8.
- Gradishar W. J., Moran M. S., Abraham J., et al (2021). Breast Cancer, Version 8.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, 18(4), 452-478.
- Huo C., Chew G., Britt K., et al (2014). Mammographic density a review on the current understanding of its association with breast cancer. *Breast Cancer Research and Treatment*, 144, 479-502.
- Kerlikowske K., Zhu W., Tosteson A., et al (2015). Identifying women with dense breasts at high risk for interval cancer: a cohort study. *Annals of internal medicine*, 162(10), 673-81.
- King V., Brooks J. D., Bernstein J. L., et al (2011). Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. *Radiology*, 260(1), 50-60.
- Lee J., Nishikawa R. (2018). Automated mammographic mammographic density estimation using a fully convolutional network. *Medical Physics*, 45, 117X 1190.
- Li S., Wei J., Chan H., et al (2018). Computer-aided assessment of mammographic density: comparison of

- supervised deep learning and feature-based statistical learning. *Physics in medicine and biology*, 63(2), 025005.
- Lv F., Jin W., Zhang X., et al (2019). Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgicalE only Er positive breast cancer. *Journal of Cellular Physiology*, 234, 11140-11148.
- Lyng E., Vejborg I., Andersen Z., et al (2019). Mammographic Density and Screening Sensitivity, Breast Cancer Incidence and Associated Risk Factors in Danish Breast Cancer Screening. *Journal of Clinical Medicine*, 8.
- Nguyen T. L., Choi Y.-H., Aung Y. K., et al (2018). Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic System. *Radiology*, 286(2), 433-442.
- Oladeru O. T., Singh A. K., Ma S. J. (2020). Association of endocrine therapy with overall survival in women with hormone recepto' positive, HERR negative, nod... negative breast cancer of favorable histology. *The Breast Journal*, 26, 2006-2010.
- Peng Fangfang, Shen Weiyi (2020). Research progress on the relationship between breast density and breast cancer in Chinese and Western women. *Chinese Journal of Cancer Prevention and Treatment*, 12(4), 469-474.
- Rahem S. M., Epsi N., Coffman F., et al (2020). Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer. *EBioMedicine*, 61.
- Román M., Sala M., Baré M., et al (2019). Changes in mammographic density over time and the risk of breast cancer: An observational cohort study. *Breast*, 46, 108-115.
- Sherratt M., Mcconnell J., Streuli C. (2016). Raised mammographic density: causative mechanisms and biological consequences. *Breast Cancer Research: BCR*, 18.
- Siegel R., Miller K., Jemal A. (2020). Cancer statistics. *CA: A Cancer Journal for Clinicians*, 70.
- Wu X., Sun A., Yu W., et al (2020). CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation. *Molecular and Cellular Endocrinology*, 512.
- Xu L., Shen J., Qu J.-L., et al (2021). FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the EU±/cyclin D1/Rb axis. *Annals of translational medicine*, 9(3), 258.
- Zhai G., Grubbs C. J., Stockard C. R., et al (2013). Diffusion Weighted Imaging Evaluated the Early Therapy Effect of Tamoxifen in an MNU-Induced Mammary Cancer Rat Mode. *PLoS ONE*, 8.
- Zhou J., Li W., Ming J., et al (2020). High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. *Anti-Cancer Drugs*, 31, 558-566.